Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — FY2022 Earnings Presentation
26 slides from Marinomed Biotech's earnings presentation, Apr 19, 2023
Slide 1: Investor Presentation Full Year 2022
Investor Presentation Full Year 2022 Andreas Grassauer, CEO Eva Prieschl-Grassauer, CSO Pascal Schmidt, CFO Korneuburg, April 19th, 2023
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed Therapeutic Areas, Pipeline, Andreas Grassauer, CEO Strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Mari
Slide 4: Highlights 2022
Highlights 2022 Delivering on our promises EUR 11.3 m + 15.5% Deal Marinosolv Stable revenues Successful year for Increase in Carragelose Solv4U Carragelose deal with Procter & + 16.5% adjusted for revenues Gamble for the U.S. Budesolv milestone U.S. patent granted © Marinomed Biotech AG 4
Slide 5: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed Therapeutic Areas, Pipeline, Andreas Grassauer, CEO Strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Mari
Slide 6: Continuous double digit growth
Continuous double digit growth Strong Carragelose business and encouraging Solv4U development Y-o-Y comparison of quarterly revenues (m€) Comments Key growth drivers 11.6 11.3 * • Adjusted for the Budesolv milestone in 2021 (€1.9m), 5.9 4.1 revenues rose from €9.7m to €11.3m (+16.5%) 2.2 2.4 2.5 2.5
Slide 7: Solid cash position
Solid cash position Low cash drain due to profitable revenues and inflows from convertible bond program • Ended December 2021 with €5.8m in cash • Raised +€7.4m in net cash through EIB1 (€6.0m), NÖBEG2 (€0.2m) and CNFP3 (€1.2m) • Received +€0.7m in milestones • Earned +€3.9m net cash through profita
Slide 8: FY 2022 Statement of profit or loss (IFRS)
FY 2022 Statement of profit or loss (IFRS) Despite missed milestone, stable full year financials €m FY 2022 FY 2021 •1 Therein: FY 2022 FY 2021 Revenues 1 11.3 11.6 Sale of goods 10.5 9.0 Other income 2 0.8 1.6 Cost of goods sold -7.1 -6.1 Materials expenses -7.3 -6.4 Margin 32.3% 32.1% Services exp
Slide 9: FY 2022 Statement of financial position (IFRS)
FY 2022 Statement of financial position (IFRS) Assets €m FY 2022 FY 2021 1 Inventories €m FY 2022 FY 2021 Assets Goods for sale 0.2 0.1 Intangible assets 1.8 2.0 Unfinished goods 0.4 0.1 Property, plant and equipment 6.2 6.4 Raw materials 0.9 0.8 Deposits and other non-current Total inventories 1.6
Slide 10: FY 2022 Statement of financial position (IFRS)
FY 2022 Statement of financial position (IFRS) Equity and liabilities €m FY 2022 FY 2021 •1 Capital increases through convertible note funding Equity and liabilities program Share capital 1.5 1.5 •2 Primarily related to EIB loan (€15.0m) and ERP/aws and Capital reserves 1 44.1 42.1 NÖBEG real estate
Slide 11: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed Therapeutic Areas, Pipeline, Andreas Grassauer, CEO Strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Mari
Slide 12: Therapeutic Areas
Therapeutic Areas Proven track record with clinically validated and patent protected technologies VIROLOGY IMMUNOLOGY • Iota-carrageenan from red seaweed: • Marinosolv technology: solubilization for broad-spectrum virus blocker hydrophobic compounds • Clinically validated efficacy against Suspension
Slide 13: Pipeline
Pipeline Late-stage projects partnering processes – high upside potential © Marinomed Biotech AG 13
Slide 14: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN • Long-term adherence to our mission MAM-1004-2 • Funding promising pipeline programs through own cash flows NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV • Expanding business with
Slide 15: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed Therapeutic Areas, Pipeline, Andreas Grassauer, CEO Strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact © Mari
Slide 16: Marinomed strategic priorities
Marinomed strategic priorities Focus on revenue generation with existing products and product candidates INHALEEN MAM-1004-2 NEW ASSETS FOR ADDITIONAL GROWTH TACROSOLV BUDESOLV CARRAVIN HIGH-VALUE PIPELINE ASSETS BUDESOLV SOLV4U CARRAGELOSE CARRAGELOSE REVENUE-GENERATING CORE BUSINESS SHORT TERM LON
Slide 17: Clinical trial with Coldamaris akut
Clinical trial with Coldamaris akut Screened N = 46 Did not fulfill Inclusion / exclusion criteria (N = 5) Safety Population Full analysis set (FAS) Intention to treat set (ITT) N = 41 Discontinued N = 1 (Study period 1) Completed allergy N = 1 (Study period 2) challenge N = 39 Non-responder N=4 Per
Slide 18: Coldamaris akut (Carrageenan/Sorbitol combi)
Coldamaris akut (Carrageenan/Sorbitol combi) Significant improvement of nasal airflow Nasal airflow: treatment effect p=0.039 70 60 50 p<0.05 40 30 20 10 0 better / equal worse Coldamaris akut Placebo In total 60% of the subjects had a benefit from treatment while 40% experienced no improvement (p<0
Slide 19: Clinical trial with Carragelose in allergy
Clinical trial with Carragelose in allergy Screened N = 47 Did not fulfill Inclusion / exclusion criteria; excluded by study site (N = 5) Full analysis set (FAS) Intention to treat set (ITT) N = 42 Discontinued N=0 Completed allergy challenge N = 42 Non-responder N=0 Per protocol set (PP) N = 42 © M
Slide 20: Carragelose in allergy: Buffered Coldamaris pro
Carragelose in allergy: Buffered Coldamaris pro Significantly reduced symptoms TNSS median 180 min Rhinorrhea 9.1 2.2 8.9 2.1 8.7 p=0.028 2 p<0.05 Median TNSS 8.5 1.9 8.3 1.8 8.1 1.7 7.9 7.7 1.6 7.5 1.5 Callergin No treatment Callergin No treatment Both, total nasal symptom score and runny nose were
Slide 21: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed delivered and presents Andreas Grassauer, CEO augmented strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact ©
Slide 22: Project status updates
Project status updates Project Status/next steps Tacrosolv Enter into a partnership within the next 9-18 months Immunology Budesolv Work on registration with Luoxin for Greater China; additional partnership for Europe (6-12 months) Autoimmune gastritis Preclinical research; apply for FFG1 grant Carr
Slide 23: Outlook
Outlook Continue Strategy 2025 with focus on near-term revenues • Strengthen existing business • Drive Carragelose in the U.S., Mexico and others and partnerships to ensure • Capitalize on recently published positive clinical data on allergy sustainable revenue growth • Support Luoxin to move to IND
Slide 24: Agenda
Agenda • Highlights 2022 Andreas Grassauer, CEO • Financials 2022 Pascal Schmidt, CFO • Marinomed delivered and presents Andreas Grassauer, CEO augmented strategy • Clinical progress Eva Prieschl-Grassauer, CSO • Project status update & outlook Andreas Grassauer, CEO • Financial calendar, contact ©
Slide 25: Financial calendar & IR contact
Financial calendar & IR contact Financial Calendar 2023 May 23, 2023 Publication of the Results Q1 2023 Record Date for participation June 11, 2023 at the Annual General Meeting June 21, 2023 6th Annual General Meeting August 17, 2023 Publication of the Results H1 2023 Stephanie Kniep November 21, 2
Slide 26: www.marinomed.com
www.marinomed.com 0) Marinomed